Inventor · disambiguated record
Anthony Coyle
Also filed as: COYLE ANTHONY · COYLE ANTHONY J · COYLE ANTHONY JOHN
20 granted patents·32 pending applications·300 citations·filing 2000–2025
95Inventor score
Top patents by PatentIndex Score
52 records- 0196US6630575B2B7-H2 PolypeptidesMILLENNIUM PHARM INC·Filed 2001·Granted Oct 7, 2003·66 cites·9 claims
- 0295US9988459B2Anti-IFNAR1 antibodies with reduced Fc ligand affinityMEDIMMUNE LLC·Filed 2017·Granted Jun 5, 2018·21 cites·2 claims
- 0393US8323653B2Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseDAMSCHRODER MELISSA·Filed 2007·Granted Dec 4, 2012·32 cites·9 claims
- 0493US7432062B2Screening methods using B7-H2 molecules, members of the B7 familyMILLENNIUM PHARM INC·Filed 2003·Granted Oct 7, 2008·32 cites·10 claims
- 0592US8883992B2Humanized anti-CD19 antibodiesMEDIMMUNE LLC·Filed 2012·Granted Nov 11, 2014·11 cites·9 claims
- 0692US7585504B2High affinity antibodies against HMGB1 and methods of use thereofMEDIMMUNE LLC·Filed 2005·Granted Sep 8, 2009·21 cites·16 claims
- 0789US6635750B1B7-H2 nucleic acids, members of the B7 familyMILLENNIUM PHARM INC·Filed 2000·Granted Oct 21, 2003·66 cites·47 claims
- 0887US9193789B2Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseCOYLE ANTHONY·Filed 2012·Granted Nov 24, 2015·16 cites·20 claims
- 0987US2024417460A1Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseVIELA BIO INC·Filed 2024·Application pending·0 cites
- 1086US9896505B2Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseMEDIMMUNE LLC·Filed 2014·Granted Feb 20, 2018·5 cites·8 claims
- 1185US7964706B2High affinity antibodies against HMGB1 and methods of use thereofMEDIMMUNE LLC·Filed 2006·Granted Jun 21, 2011·10 cites·16 claims
- 1283US10000553B2CD40L-specific TN3-derived scaffolds and methods of use thereofMEDIMMUNE LLC·Filed 2012·Granted Jun 19, 2018·6 cites·19 claims
- 1383US2025101116A1Anti-ifnar1 antibodies with reduced fc ligand affinityASTRAZENECA AB·Filed 2023·Application pending·0 cites
- 1482US10301390B2Anti-IFNAR1 antibodies with reduced Fc ligand affinityASTRAZENECA AB·Filed 2018·Granted May 28, 2019·2 cites·3 claims
- 1581US10829553B2Interferon beta antibodies and uses thereofPFIZER·Filed 2017·Granted Nov 10, 2020·2 cites·17 claims
- 1681US8153131B2High affinity antibodies against HMGB1 and methods of use thereofWU HERREN·Filed 2009·Granted Apr 10, 2012·4 cites·18 claims
- 1779US8129130B2High affinity antibodies against HMGB1 and methods of use thereofWU HERREN·Filed 2011·Granted Mar 6, 2012·5 cites·4 claims
- 1878US12448439B2Interferon beta antibodies and uses thereofPFIZER·Filed 2023·Granted Oct 21, 2025·0 cites·9 claims
- 1978US2023242619A1Compositions comprising a tn3 scaffold and methods of using the sameVIELA BIO INC·Filed 2022·Application pending·0 cites
- 2077US11104720B2Nucleic acids encoding a Tn3 scaffold comprising a CD40L-specific monomer subunitVIELA BIO INC·Filed 2018·Granted Aug 31, 2021·1 cites·22 claims
- 2174US11555062B2Methods of administering a composition comprising a Tn3 scaffold and a CD40L-specific monomerVIELA BIO INC·Filed 2021·Granted Jan 17, 2023·0 cites·39 claims
- 2273US2021061906A1Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseVIELA BIO INC·Filed 2020·Application pending·0 cites
- 2373US2020172625A1Anti-ifnar1 antibodies with reduced fc ligand affinityASTRAZENECA AB·Filed 2019·Application pending·0 cites
- 2472US2025257120A1Compositions comprising a tn3 scaffold and methods of using the sameVIELA BIO INC·Filed 2025·Application pending·0 cites
- 2566US12110324B2Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)FLAGSHIP PIONEERING INNOVATIONS VI LLC·Filed 2023·Granted Oct 8, 2024·0 cites·23 claims
- 2666US2020055944A1Anti-ifnar1 antibodies with reduced fc ligand affinityASTRAZENECA AB·Filed 2019·Application pending·0 cites
- 2766US2011059078A1Anti-ifnar1 antibodies with reduced fc ligand affinityMEDIMMUNE LLC·Filed 2009·Application pending·0 cites
- 2866US2009269783A1B7-H2 molecules, novel members of the B7 family and uses thereofCOYLE ANTHONY J·Filed 2008·Application pending·0 cites
- 2965US11858986B2Interferon beta antibodies and uses thereofPFIZER·Filed 2020·Granted Jan 2, 2024·0 cites·18 claims
- 3064US2025109193A1Antigen Binding Molecules Targeting Thymic Stromal Lymphopoietin (TSLP)FLAGSHIP PIONEERING INNOVATIONS VI LLC·Filed 2024·Application pending·0 cites
- 3163US2018273621A1Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseVIELA BIO INC·Filed 2018·Application pending·0 cites
- 3262US2010143372A1Interferon alpha-induced pharmacodynamic markersMEDIMMUNE LLC·Filed 2007·Application pending·0 cites
- 3361US2015044222A1Interferon alpha-induced pharmacodynamic markers and uses thereofMEDIMMUNE LLC·Filed 2014·Application pending·0 cites
- 3460US2008279851A1Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseMEDIMMUNE LLC·Filed 2008·Application pending·0 cites
- 3558US2011059100A1C/CLP Antagonists And Methods Of Use ThereofMEDIMMUNE LLC·Filed 2009·Application pending·0 cites
- 3657US2014302058A1Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseasesMEDIMMUNE LLC·Filed 2014·Application pending·0 cites
- 3756US2010261172A1Interferon alpha-induced pharmacodynamic markersMEDIMMUNE LLC·Filed 2008·Application pending·0 cites
- 3856US2017121771A1Interferon alpha-induced pharmacodynamic markers and uses thereofMEDIMMUNE LLC·Filed 2016·Application pending·0 cites
- 3953US2015132313A1Interferon alpha-induced pharmacodynamic markersMEDIMMUNE LLC·Filed 2014·Application pending·0 cites
- 4052US2007071746A1C/CLP antagonists and methods of use thereofMEDIMMUNE INC·Filed 2006·Application pending·0 cites
- 4152US2017101468A1Human anti il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseasesMEDIMMUNE LTD·Filed 2016·Application pending·0 cites
- 4251US2015147336A1Interferon alpha-induced pharmacodynamic markers and uses thereofMEDIMMUNE LLC·Filed 2015·Application pending·0 cites
- 4351US2013266566A1Methods of inhibiting fibrosis using anti-pai-1 antibodiesANDERSON IAN·Filed 2013·Application pending·0 cites
- 4449US2010260770A1Il-33 in inflammatory diseaseMEDIMMUNE LLC·Filed 2008·Application pending·0 cites
- 4549US2011243929A1Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune diseaseMEDIMMUNE LLC·Filed 2010·Application pending·0 cites
- 4647US2011008365A1Methods of treating sclerodermaCOYLE ANTHONY·Filed 2008·Application pending·0 cites
- 4747US2012034212A1Human Anti-IL-6 Antibodies With Extended In Vivo Half-Life And Their Use In Treatment Of Oncology, Autoimmune Diseases And Inflammatory DiseasesBOWEN MICHAEL·Filed 2010·Application pending·0 cites
- 4847US2005202013A1Novel Th2-specific molecules and uses thereofMILLENNIUM PHARM INC·Filed 2005·Application pending·0 cites
- 4946US2010093611A1Compounds and methods for treating or preventing autoimmune diseasesHORRIGAN STEPHEN K·Filed 2008·Application pending·0 cites
- 5045US2011287022A1Interferon alpha-induced pharmacodynamic markersYAO YIHONG·Filed 2009·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →